Avibactam restores the susceptibility of clinical isolates of Stenotrophomonas maltophilia to aztreonam

MOJICA, MARIA F.; BARNES, MELISSA D.; TARACILA, MAGDALENA A.; LIPUMA, JOHN J.; JACOBS, MICHAEL R.; BONOMO, ROBERT A.; VILA, ALEJANDRO J.; PAPP-WALLACE, KRISZTINA M.; RUTTER, JOSEPH D.; WALSH, THOMAS J.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

AMER SOC MICROBIOLOGY

Año: 2017 vol. 61

0066-4804

Stenotrophomonas maltophilia is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for S. maltophilia is urgent. We demonstrate the in vitro efficacy of aztreonam-avibactam (ATM-AVI) against S. maltophilia and kinetically characterize the inhibition of the L2 β-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of S. maltophilia, addressing an unmet medical need.